User:Mr. Ibrahem/Dolasetron

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Dolasetron
Clinical data
AHFS/Drugs.comMonograph
MedlinePlusa601001
Pregnancy
category
  • B (US)
Routes of
administration		Intravenous, by mouth
Drug class5-HT3 receptor blocker[1]
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding69 to 77%
Elimination half-life8.1 hours
Identifiers
  • (3R)-10-oxo-8-azatricyclo[5.3.1.03,8]undec-5-yl 1H-indole-3-carboxylate
Chemical and physical data
FormulaC19H20N2O3
Molar mass324.380 g·mol−1
3D model (JSmol)
  • [H]C35C[C@@]4([H])CC(OC(=O)c1c[nH]c2ccccc12)C[C@@]([H])(C3)N4CC5=O
  • InChI=1S/C19H20N2O3/c22-18-10-21-12-5-11(18)6-13(21)8-14(7-12)24-19(23)16-9-20-17-4-2-1-3-15(16)17/h1-4,9,11-14,20H,5-8,10H2/t11-,12+,13-,14- checkY
  • Key:UKTAZPQNNNJVKR-YXSUXZIUSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Dolasetron, sold under the brand name Anzemet, is a medication used for postoperative and chemotherapy-induced nausea and vomiting.[1][2] Other uses may include gastroenteritis and hyperemesis gravidarum.[1] It does not work for motion sickness.[1] It is taken by mouth; and less commonly by injection into a vein.[2]

Common side effects include headache, tiredness, dizziness, and diarrhea.[1] Other side effects may include QT prolongation and anaphylaxis.[1][2] While there is no evidence of harm in pregnancy, such use is not well studied.[3] It is a 5-HT3 receptor blocker.[1]

Dolasetron was patented in 1986 and approved for medical use in 1997.[4] It is on the World Health Organization's List of Essential Medicines.[5] It is available as a generic medication.[1] In the United States it costs about 75 USD per dose.[6] Some versions have been discontinued in the United States.[7]

References[edit]

  1. ^ a b c d e f g h i j "Serotonin 5-HT3 Receptor Antagonists". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 8 May 2021. Retrieved 26 December 2021.
  2. ^ a b c d e "Dolasetron Monograph for Professionals". Drugs.com. Archived from the original on 22 January 2021. Retrieved 26 December 2021.
  3. ^ "Dolasetron (Anzemet) Use During Pregnancy". Drugs.com. Archived from the original on 24 November 2020. Retrieved 26 December 2021.
  4. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 448. ISBN 9783527607495. Archived from the original on 2021-09-30. Retrieved 2020-11-28.
  5. ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
  6. ^ "Anzemet Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 26 December 2021.
  7. ^ "Drugs@FDA: FDA-Approved Drugs". www.accessdata.fda.gov. Archived from the original on 22 March 2021. Retrieved 26 December 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Dolasetron&oldid=1222469151"